Community Research and Development Information Service - CORDIS

FP6

AUTOROME — Result In Brief

Project ID: 5264
Funded under: FP6-LIFESCIHEALTH
Country: Germany

Personal treatment for rare autoimmune diseases

Rare autoimmune diseases are affecting the quality of life of many Europeans, and there is a lack of sufficient prognostic and therapeutic tools. A European research network was established to shed light on these disorders with the aim of realising a personalised medicine approach.
Personal treatment for rare autoimmune diseases
The term autoimmune diseases (ADs) refers to a group of disorders with variable clinical symptoms which involve an autoimmune pathogenesis. They may affect a single or many organs, and in most of the cases they cause significant and chronic morbidity and disability. Only a few of them are well studied, while the vast majority of ADs are rare without epidemiology data.

The EU-funded project Autorome established a network of excellence connecting many European research centres in the field of ADs. The consortium utilised post-genomic tools to characterise pathophysiological mechanisms of rare ADs with the ultimate and long-term goal of developing personalised diagnostic and therapeutic strategies.

Autorome scientists focused on the antibody-mediated ADs, such as systemic lupus erythematosus (SLE), systemic scleroderma (SSC), anti-phospholipid syndrome (APS), autoimmune lymphoproliferative syndrome (ALPS) and Stiff-Person syndrome (SPS).

The synergistic research of the Autorome network enhanced knowledge on the molecular processes involved in Ads, thus significantly improving their classification and characterisation. Moreover, essential clinical data were collected in order to deeply understand the role of genetic and environmental factors in the pathogenesis of Ads.

The initiatives which were triggered and promoted by the network significantly advanced our knowledge regarding ADs. State-of-the-art technologies were combined in an effective and novel manner yielding essential information on the humoral, cellular and molecular basis of these diseases. The main idea behind every study was the individualistic features of the interplay between genomic and environmental factors in each human as related to rare ADs.

The knowledge established over the last 20 years in the field was collected and re-analysed by Autorome scientists with recently established cutting-edge technologies. The produced data were integrated in a database accessible to the members of the consortium.

Autorome’s achievements are essential for the efficient cooperation of the European scientific society of rare ADs. Through this joint operation, unknown sides of ADs were uncovered, new tools for their study were developed and, more importantly, all the current information was collected and integrated in one publicly available database.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top